Blood Res.  2021 Dec;56(4):315-321. 10.5045/br.2021.2021165.

Blood management strategies in congenital Glanzmann thrombasthenia at a hematology referral center

• Kasinathan G
• Sathar J

• KMID: 2524091
• DOI: http://doi.org/10.5045/br.2021.2021165

Abstract

Background
Glanzmann thrombasthenia is associated with abnormalities in the glycoprotein IIb/IIIa receptor. This study, conducted at Ampang Hospital, Malaysia, aimed to assess outcomes of blood management strategies for Glanzmann thrombasthenia.
Methods
Ten patients with Glanzmann thrombasthenia aged 9 years (2009‒2018) were examined. Data on clinical characteristics, transfusion practices, and patient blood management were obtained from medical records. Patient blood management methods included parenteral iron, erythropoietin, hormonal pills, intrauterine progesterone contraceptive devices, tranexamic acid, and recombinant factor VIIa. Primary outcomes were hemoglobin levels and the proportion of patients who received blood transfusion. Secondary outcomes were morbidity and mortality.
Results
The median age at diagnosis was 8.2 years (range, 1‒15 yr). The female-to-male ratio was 9:1. Eight patients had type 2 disease (5‒20% of normal GPIIb/IIIa), and two patients had type 1 disease (normal GPIIb/IIIa ＜5%). All patients had iron deficiency. All female patients presented with significant menorrhagia. Other bleeding symptoms included epistaxis, spontaneous skin bruising, hemoptysis, gingival bleeding, knee hemarthrosis, and pelvic hematoma. No patient experienced life-threatening bleeding. Our patients had a mean hemoglobin level of 5.6 g/dL at diagnosis. All patients were optimized using non-transfusion methods as described above. Our patient had a current mean hemoglobin level of 11 g/dL. Approximately 70% (7/10) of patients did not experience receiving blood transfusions in the last 5 years. No patient experienced non-transfusion-related morbidities such as sepsis, thromboembolism, or cardiorespiratory events.
Conclusion
High cost, transfusion-related adverse events, and immunomodulation could be effectively prevented by avoiding unnecessary blood transfusions.

Keyword

Glanzmann thrombasthenia; Hemoglobin; Erythropoietin; Menorrhagia; Iron

Figure

• 

  Fig. 1 Computed tomography of the pelvis demonstrating a hetero-geneously enhanced solid cystic mass arising from the posterior wall of the uterus measuring 13.5×10×13.3 cm.

• 

  Fig. 2 Hb level at baseline and with PBM. Abbreviations: Hb, hemoglobin; PBM, patient blood management.

Reference

1. Pittman MA Jr, Graham JB. 1964; Glanzmann's thrombopathy: an autosomal recessive trait in one family. Am J Med Sci. 247:293–303. DOI: 10.1097/00000441-196403000-00008. PMID: 14130322.

2. Nurden AT, Pillois X, Fiore M, et al. 2015; Expanding the mutation spectrum affecting αIIβ3 integrin in Glanzmann thro-mbasthenia: screening of the ITGA2B and ITGB3 genes in a large international cohort. Hum Mutat. 36:548–61. DOI: 10.1002/humu.22776. PMID: 25728920.

3. Tholouli E, Hay CR, O'Gorman P, Makris M. 2004; Acquired Glanzmann's thrombasthenia without thrombocytopenia: a severe acquired autoimmune bleeding disorder. Br J Haematol. 127:209–13. DOI: 10.1111/j.1365-2141.2004.05173.x. PMID: 15461628.

4. Nurden AT, Fiore M, Nurden P, Pillois X. 2011; Glanzmann thro-mbasthenia: a review of ITGA2B and ITGB3 defects with emphasis on variants, phenotypic variability, and mouse models. Blood. 118:5996–6005. DOI: 10.1182/blood-2011-07-365635. PMID: 21917754.

5. Miller JL. 2009; Glycoprotein analysis for the diagnostic evaluation of platelet disorders. Semin Thromb Hemost. 35:224–32. DOI: 10.1055/s-0029-1220330. PMID: 19408195.

6. Hendrickson JE, Hillyer CD. 2009; Noninfectious serious hazards of transfusion. Anesth Analg. 108:759–69. DOI: 10.1213/ane.0b013e3181930a6e. PMID: 19224780.

7. Isbister J. 2005; Why should health professionals be concerned about blood management and blood conservation? Updates in Blood Conservation and Transfusion Alternatives. International Foundation for Patient Blood Management. 2:3–7.

8. Spahn DR, Goodnough LT. 2013; Alternatives to blood transfusion. Lancet. 381:1855–65. DOI: 10.1016/S0140-6736(13)60808-9. PMID: 23706802.

9. Toogeh G, Sharifian R, Lak M, Safaee R, Artoni A, Peyvandi F. 2004; Presentation and pattern of symptoms in 382 patients with Glanzmann thrombasthenia in Iran. Am J Hematol. 77:198–9. DOI: 10.1002/ajh.20159. PMID: 15389911.

10. Jobe SM. 2009; Glanzmann thrombasthenia. In: Hillyer CD, Shaz BH, Zimring JC, Abshire TC, eds. Transfusion medicine and hemostasis: clinical and laboratory aspects. Burlington, MA:. Elsevier,. 467–8.

11. Solh T, Botsford A, Solh M. 2015; Glanzmann's thrombasthenia: pathogenesis, diagnosis, and current and emerging treatment options. J Blood Med. 6:219–27. DOI: 10.2147/JBM.S71319. PMID: 26185478. PMCID: PMC4501245.

12. George JN, Caen JP, Nurden AT. 1990; Glanzmann's thrombasthenia: the spectrum of clinical disease. Blood. 75:1383–95. DOI: 10.1182/blood.V75.7.1383.1383. PMID: 2180491.

13. Reichert N, Seligsohn U, Ramot B. 1975; Clinical and genetic aspects of Glanzmann's thrombasthenia in Israel: report of 22 cases. Thromb Diath Haemorrh. 34:806–20. DOI: 10.1055/s-0038-1653719. PMID: 1239828.

14. Farsinejad A, Abolghasemi H, Kazemi A, et al. 2011; Classification of Iranian patients with Glanzmann's thrombasthenia using a flow cytometric method. Platelets. 22:321–7. DOI: 10.3109/09537104.2011.556275. PMID: 21526886.

15. Bevan JA, Maloney KW, Hillery CA, Gill JC, Montgomery RR, Scott JP. 2001; Bleeding disorders: a common cause of menorrhagia in adolescents. J Pediatr. 138:856–61. DOI: 10.1067/mpd.2001.113042. PMID: 11391329.

16. Chitlur M, Rajpurkar M, Recht M, et al. 2017; Recognition and management of platelet-refractory bleeding in patients with Glanzmann's thrombasthenia and other severe platelet function disorders. Int J Gen Med. 10:95–9. DOI: 10.2147/IJGM.S128953. PMID: 28435309. PMCID: PMC5388206.

17. Khalafallah AA, Yan C, Al-Badri R, et al. 2016; Intravenous ferric carboxymaltose versus standard care in the management of postoperative care anemia: a prospective, open-label, randomised controlled trial. Lancet Haematol. 3:e415–25. DOI: 10.1016/S2352-3026(16)30078-3.

18. Law RHP, Wu G, Leung EWW, et al. 2017; X ray crystal structure of plasmin with tranexamic acid-derived active site inhibitors. Blood Adv. 1:766–71. DOI: 10.1182/bloodadvances.2016004150. PMID: 29296720. PMCID: PMC5728053.

19. Franchini M, Mengoli C, Marietta M, et al. 2018; Safety of intravenous tranexamic acid in patients undergoing majororthopaedic surgery: a meta-analysis of randomised controlled trials. Blood Transfus. 16:36–43. DOI: 10.2450//2017.0219-17. PMID: 29337665. PMCID: PMC5770313.

20. Matteson KA, Rahn DD, Wheeler TL 2nd, et al. 2013; Nonsurgical management of heavy menstrual bleeding: a systematic review. Obstet Gynecol. 121:632–43. DOI: 10.1097/AOG.0b013e3182839e0e. PMID: 23635628. PMCID: PMC4414119.

21. Hillard PA. 2014; Menstrual suppression: current perspectives. Int J Womens Health. 6:631–7. DOI: 10.2147/IJWH.S46680. PMID: 25018654. PMCID: PMC4075955.

22. Allen GA, Monroe DM 3rd, Roberts HR, Hoffman M. 2000; The effect of factor X level on thrombin generation and the procoagulant effect of activated factor VII in a cell-based model of coagulation. Blood Coagul Fibrinolysis. 11(Suppl 1):S3–7. DOI: 10.1097/00001721-200004001-00002. PMID: 10850556.

23. Lindley CM, Sawyer WT, Macik BG, et al. 1994; Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther. 55:638–48. DOI: 10.1038/clpt.1994.80. PMID: 8004880.